{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"123"},{"groupId":"OG007","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"123"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study treatment(s). A TEAE was defined as any adverse event that started or worsened after the first dose of study drug.","groups":[{"description":"INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.","id":"OG000","title":"Part 1A: INCB001158 50 mg"},{"description":"INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.","id":"OG001","title":"Part 1A: INCB001158 75 mg"},{"description":"INCB001158 administered orally at 100mg BID in participants with advanced/metastatic solid tumors.","id":"OG002","title":"Part 1A: INCB001158 100 mg"},{"description":"INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.","id":"OG003","title":"Part 1A: INCB001158 150 mg"},{"description":"INCB001158 was administered orally at 50 mg BID in combination with pembrolizumab at 200 mg intravenously (IV) every 3 weeks (Q3W).","id":"OG004","title":"Part 1B: INCB001158 50 mg + Pembrolizumab"},{"description":"INCB001158 was administered orally at 75 mg BID in combination with pembrolizumab at 200 mg IV Q3W.","id":"OG005","title":"Part 1B: INCB001158 75 mg + Pembrolizumab"},{"description":"INCB001158 was administered orally at 100 mg BID in combination with pembrolizumab at 200 mg IV Q3W.","id":"OG006","title":"Part 1B and Part 3: INCB001158 100 mg + Pembrolizumab"},{"description":"INCB001158 was administered orally at 50 mg BID in combination with pembrolizumab at 200 mg IV Q3W to participants with moderately impaired renal function.","id":"OG007","title":"Part 1C: INCB001158 50 mg + Pembrolizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population: all participants who received at least 1 dose of INCB001158 or pembrolizumab. Data collected through study completion have been reported.","reportingStatus":"POSTED","timeFrame":"up to study completion (up to approximately 3.5 years)","title":"Number of Participants With Any Treatment-emergent Adverse Event (TEAE)","type":"PRIMARY","unitOfMeasure":"Participants"}